Hansa Biopharma licenses IDEFIRIX to SERB Pharmaceuticals in €115M deal
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Subscribe To Our Newsletter & Stay Updated